Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 1.1227
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 891603780.0
- FreeCF/Share -1.0763
- PFCF -2.5658
- PE -2.2966
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | Goldman | Neutral | Sell | -- | $1 | July 15, 2025 |
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Recover Losses - Contact Levi & Korsinsky Before July 14, 2025
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152288&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
IOVA ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. - July 14, 2025 Deadline
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152263&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
Published: June 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 9, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Securities Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Represents Shareholders
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152251&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Read More
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, 2025, UBS analysts reportedly slashed their rating on Iovance shares from Buy to Neutral and issued a stark price target cut—from $17 to just $2—citing mounting concerns over the drug's commercial rollout and the company's ability to meet market expectations. The analyst downgrade comes as Iovance faces additional scrutiny in the form of securities class action litigation filed …
Read More
IOVA INVESTORS: Iovance Biotherapeutics, Inc. Shareholders Are Reminded to Contact BFA Law Before The Expiration of The Upcoming July 14 Class Action Deadline
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 14, 2025 Deadline
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=152005&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
Read More
Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151905&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.
Read More
IOVA INVESTOR NOTICE: Iovance Biotherapeutics, Inc. Investors with Losses are Notified of the Ongoing Securities Fraud Class Action and July 14 Deadline – BFA Law (NASDAQ:IOVA)
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151889&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have Opportunity to Lead Iovance Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").
Read More
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Published: June 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151866&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / June 5, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NasdaqGM:IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period").
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025 - Contact Levi & Korsinsky
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151847&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
Securities Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Represents Shareholders
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151795&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Read More
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”).
Read More
Contact Levi & Korsinsky by July 14, 2025 Deadline to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
Read More
July 14, 2025 Deadline: Join Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151793&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151782&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
SAN FRANCISCO, CA / ACCESS Newswire / June 5, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.
Read More
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151773&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151723&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.
Read More
IOVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Frederick G. Vogt
- Employees 838